A recent network meta-analysis presented at HFSA 2026 displays finerenone’s favorable safety profile and comparatively greater reduction of acute kidney injury risk.
|Articles|July 12, 2021
ASPC 2021 Virtual Summit on CVD Prevention Taking Place July 23-25
Author(s)HCP Live
The virtual sessions will cover a litany of topics in the greater spectrum of cardiovascular disease prevention and care.
Advertisement
The American Society for Preventive Cardiology (ASPC) has announced their 2021 Virtual Summit on CVD Prevention will take place from July 23-25, 2021.
The ASPC emphasized the event will focus on the inclusiveness and the care of one and all at risk for cardiovascular disease.
The event is for a wide variety of physicians, researchers, and other healthcare professionals to engage with cutting-edge lectures, lively debates, and practical applications.
Presenters will explore the broad spectrum of preventive cardiology led by world-renowned experts in the field of cardiology.
Topics covered will include:
- Emerging Therapies for Lipid Management
- CAC vs. Biomarkers
- Chest Pain Guidelines and Imaging
- Prevention of Heart Failure
- Atrial Fibrillation
- PAD Evaluation, Treatment, and Management
- Practical Application of New Prevention Therapies
- CVD Prevention in Special Populations
Advertisement
Related to this article
A new analysis of the phase 3 ATTRibute-CM study, presented at HFSA 2026, may indicate a connection between the number of hospitalizations and mortality risk.
Catch up on HCPLive’s first-half Fall Clinical 2026 coverage, including new psoriasis and atopic dermatitis data and expert insights on HS and vitiligo.
New ARCADIA and OLYMPIA LTE data show nemolizumab sustained skin clearance and itch relief for up to 3 years in atopic dermatitis and prurigo nodularis.
Two-year ICONIC-LEAD data show oral icotrokinra sustained PASI 90 and IGA 0/1 responses in more than 70% of adults and adolescents with plaque psoriasis.
New TOGETHER-PsO data show ixekizumab plus tirzepatide drove broader immune and metabolic biomarker changes than ixekizumab alone in psoriasis and obesity.
In this session, Cheri Frey, MD, shared a framework for evaluating skincare products, from ingredient plausibility to clinically meaningful results.
Andrea Murina, MD, reviewed strategies for optimizing HS biologics, combining therapies, and reconsidering the role of surgery.
Advertisement
Advertisement
Trending on HCPLive
1
Second-Line Therapy in Fibrillary GN: Secondary Causes and Rituximab Data
2
Ixekizumab, Tirzepatide Broaden Biomarker Effects in Psoriasis, Obesity
3
Brepocitinib Improves Cutaneous Sarcoidosis by Week 4: Aaron Mangold, MD
4
Tips on Optimizing HS Biologics, Combinations, and Surgery
5